Managing Infliximab Reinduction After Temporary Discontinuation of Drug

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2016-07-31

Study Completion Date

2019-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of the project is to determine what is the best schedule for restarting infliximab in patients with inflammatory bowel disease (IBD) specifically ulcerative colitis and Crohn's disease, who have undergone infliximab infusions before. The primary endpoint would be the failure rate; the need to discontinue infliximab or change treatment. A secondary aim will be to determine if infliximab drug and antibody levels can predict clinical outcomes at 1 year. Other secondary outcomes include comparing short-term and long-term steroid free remission rate, and serum and fecal inflammatory markers in response to infliximab.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Stop Infliximab in Patients With Crohn's Disease

NCT00571337

Crohn Disease

COMPLETED PHASE3

Improving Treatment of Inflammatory Bowel Diseases Through Better Understanding Infliximab Drug and Antibody Levels

NCT01787786

Crohn's Disease Ulcerative Colitis

WITHDRAWN

Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease

NCT00325078

Chronic Granulomatous Disease Crohn'S-like IBD Inflammatory Bowel Disease (IBD)

TERMINATED PHASE1/PHASE2

Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission

NCT01817426

Crohn Disease

COMPLETED PHASE4

Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease

NCT04974099

Crohn Disease

TERMINATED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Bowel Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Infliximab at weeks 0,2, and 6

In this arm subjects will receive re-induction treatment of infliximab at weeks 0,2, and 6.

Group Type EXPERIMENTAL

Infliximab at weeks 0,2, and 6

Intervention Type DRUG

Infliximab at weeks 0,4, and 8

In this arm subjects will receive re-induction treatment of infliximab at weeks 0, 4, and 8

Group Type EXPERIMENTAL

Infliximab at weeks 0,4, and 8

Intervention Type DRUG

Infliximab at weeks 0, and 8

In this arm subjects will not be randomized. They will receive re-induction therapy weeks 0 and 8.

Group Type ACTIVE_COMPARATOR

Infliximab at weeks 0 and 8

Intervention Type DRUG

For physicians who do not feel comfortable enrolling patients in a randomized trial of infliximab re-induction they will have the option of enrolling their patients in an arm that resumes maintenance therapy only instead at 0 and 8 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Infliximab at weeks 0,2, and 6

Intervention Type DRUG

Infliximab at weeks 0,4, and 8

Intervention Type DRUG

Infliximab at weeks 0 and 8

For physicians who do not feel comfortable enrolling patients in a randomized trial of infliximab re-induction they will have the option of enrolling their patients in an arm that resumes maintenance therapy only instead at 0 and 8 weeks.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects 18 years or older who are willing and able to provide informed consent
* HIstory of IBD (Crohn's disease, ulcerative colitis, indeterminate colitis) by standard clinical, histological, and radiographic date.
* History of stable clinical response to prior IFX induction and regular maintenance dosing, as determine by enrolling clinician.
* Prior to drug holiday, was on stable dose of infliximab for at least 3 infusions at regular maintenance intervals
* Infliximab drug holiday for at least 12 weeks.